News for Vir Biotechnology, Inc. (VIR)

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from a 24-week subgroup analysis of its ongoing Phase 2 SOLSTICE trial in c

We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where Vir Biotechnology, Inc. (NASDAQ:VIR) stands against other stocks under $10 that will triple. As we delve into the discussion on stocks that will triple, we must shed light on the […]

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first patient in its Phase 3 ECLIPSE registrational program. The ECLIPSE registrati

VIR's T-cell engagers have potential in oncology and showed promise with initial data in January 2025. Read my thoughts about VIR's near-term catalysts.

Vir Biotechnology Inc's innovative approach to immunology positions it as a leader in combating infectious diseases and cancer.Strategic partnerships and fundi

R&D Expenses: $507 million in 2024, down from $580 million in 2023.G&A Expenses: $119 million in 2024, down from $174 million in 2023.Net Loss: $522 million in

Feb 26, 2025 / 09:30PM GMTOperator Hello. Welcome to VR Biotechnologies' 4th quarter and full year 2024 financial results and business update call. As a reminde

Vir Biotechnology (VIR) delivered earnings and revenue surprises of 10.59% and 15.22%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Vir Biotechnology Inc (VIR) has announced its financial results for the fourth quarter and full year ending December 31, 2024, alongside a corporate update. The

Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31,

Revenue: $12.4 million for Q4 2024, surpassing the estimated $8.14 million.Earnings Per Share (EPS): $(0.76) for Q4 2024, better than the estimated $(0.87).Net

Vir Biotechnology Inc (VIR), a clinical-stage biopharmaceutical company, has announced that it will provide a corporate update and report its financial results

This is our list of the best health care stocks based on the highest return over the last 30 days.

**media[527277,527278]**

We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look at where Vir Biotechnology, Inc.

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals

Vir Biotechnology (VIR) stock was upgraded by Morgan Stanley after the company posted trial data for two antitumor agents developed with Sanofi (SNY). Read more here.

On January 8, 2025, Vicki Sato, a Director at Vir Biotechnology Inc (VIR), sold 10,960 shares of the company, as reported in the SEC Filing. Following this tran

Vir Biotechnology's recent share price rally is driven by their promising cancer program. Having shot to over a $1.5B market cap, see if VIR stock is a Buy now.